Close Menu

NEW YORK (GenomeWeb) – Asuragen announced today it has expanded its CE mark on two BCR-ABL tests to enable their use on a Roche platform.

The multiplexed qPCR tests are part of the firms QuantideX portfolio and support therapy cessation for long-term responders to tyrosine kinase inhibitor therapies.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.